The fertility conversation is the part of testosterone care that men are most likely to be shortchanged on, and it is the one with the most permanent consequences. This Part closes the loop: how to protect fertility, how to try to recover it, and how to stop therapy well.
Before Any Androgen Exposure
- Ask about fertility intent explicitly and document it.
- In any man with current or possible future fertility intent, offer semen analysis before initiation as a baseline.
- Offer sperm cryopreservation and explain that it is the only guaranteed preservation strategy.
- For men with fertility intent, prefer fertility-sparing management over testosterone monotherapy — refer to reproductive urology.
Fertility-Sparing and Fertility-Restoring Options
| Agent | Mechanism | Typical role | Notes |
|---|---|---|---|
| Human chorionic gonadotropin (hCG) | LH receptor agonist; maintains intratesticular testosterone and Leydig function | Maintaining fertility during therapy, or restoring the axis after suppression | Off-label for this use in many contexts; commonly specialist-directed; requires injection |
| Clomiphene citrate | SERM; blocks central estrogen negative feedback, raising LH and FSH | Raising endogenous testosterone in secondary hypogonadism where fertility matters | Off-label in men in the United States; oral; monitor testosterone and estradiol |
| Enclomiphene | Trans-isomer of clomiphene with SERM activity | Similar role to clomiphene | Availability and regulatory status vary; compounded versions are not FDA-approved |
| Recombinant FSH | Directly supports Sertoli cell function and spermatogenesis | Added when hCG alone does not restore sperm production | Specialist-directed; expensive |
| Anastrozole | Aromatase inhibitor; reduces estradiol-mediated feedback | Selected men with a low testosterone-to-estradiol ratio, typically obese | Off-label; narrow role; risk of over-suppressing estradiol |
Supported by consistent observational series, smaller randomized trials, and specialty society guidance; large outcome trials are limited and several uses are off-label.
Recovery of spermatogenesis after discontinuing exogenous testosterone commonly takes six to twenty-four months, and is influenced by duration of exposure, dose, prior fertility, age, and baseline testicular function. Most men recover; a minority do not. Say this clearly rather than implying recovery is automatic.
Discontinuing Therapy
- Reasons to stop include unmanageable erythrocytosis, new prostate cancer, planned conception, absence of symptomatic benefit after an adequate trial, patient preference, and new contraindications.
- Expect a symptomatic withdrawal period as the axis recovers — fatigue, low mood, and low libido are common and can be worse than before treatment.
- Tapering has no proven advantage over stopping for most men, but a taper can make the transition more tolerable.
- In men who want the axis to recover, hCG with or without a SERM under specialist direction can shorten recovery.
- Recheck testosterone, LH, and FSH after a washout — typically six to twelve weeks for short-acting formulations, longer for pellets and undecanoate — to determine the true baseline.
- If no symptomatic benefit was achieved after three to six months at a therapeutic level, discontinuation is appropriate and should be framed as diagnostic information, not failure.
Referral Triggers
| Refer to | When |
|---|---|
| Urology | PSA rise greater than 1.4 ng/mL in 12 months; new prostate nodule; PSA above the age-appropriate threshold; significant lower urinary tract symptoms; suspected testicular mass |
| Reproductive urology | Any fertility intent in a man with hypogonadism; azoospermia or oligospermia; prior anabolic steroid exposure with fertility goals; varicocele |
| Endocrinology | Suspected pituitary pathology; hyperprolactinemia; multiple anterior pituitary hormone deficiencies; Klinefelter syndrome; hemochromatosis; refractory management |
| Hematology | Recurrent erythrocytosis requiring repeated phlebotomy; suspected polycythemia vera; unprovoked VTE |
| Sleep medicine | Suspected or worsening obstructive sleep apnea |
| Cardiology | New atrial fibrillation; decompensated heart failure; recent acute coronary syndrome |
| Behavioral health | Anabolic steroid use disorder; body dysmorphic features; depression not responding to appropriate first-line care |
Stopping well
A 38-year-old man has been on testosterone cypionate 100 mg weekly for three years. He and his wife now want to conceive. He asks how quickly he can stop and start trying. His testicular volume is reduced. He has not had a semen analysis.
What do you tell him, and what is the plan?